Aarti Drugs Ltd (AARTIDRUGS) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 524348 | NSE: AARTIDRUGS | Pharmaceuticals & Drugs | Small Cap

Aarti Drugs Share Price

404.95 -3.35 -0.82%
as on 05-Dec'25 16:59

Aarti Drugs Ltd (AARTIDRUGS) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 524348 | NSE: AARTIDRUGS | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Aarti Drugs

Based on:

Overall Rating
Login to view analysis. Bole Toh

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

Aarti Drugs stock performance -

Key Ratios
mw4me loader
P/E Ratio (CD):
18.72
Market Cap:
3,726.6 Cr.
52-wk low:
312.5
52-wk high:
575

Is Aarti Drugs Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Aarti Drugs: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Aarti Drugs Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 18%18.1%17.3%17%21.4%34.5%20.8%15.5%15%13.1%-
Value Creation
Index
0.30.30.20.20.51.60.50.10.1-0.1-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 1,1401,1951,2441,5611,8062,1552,4892,7162,5292,3872,477
Sales YoY Gr.-4.9%4.1%25.5%15.7%19.3%15.5%9.1%-6.9%-5.6%-
Adj EPS 7.18.68.79.214.829.822.11818.718.421.8
YoY Gr.-20.7%2%5.8%60.6%101.1%-25.8%-18.9%4%-1.4%-
BVPS (₹) 36.941.948.357.67098111.9128.8139.4150160.9
Adj Net
Profit
68.781.782.387.1138278205166172168199
Cash Flow from Ops. 13317569.814325115570.4133359245-
Debt/CF from Ops. 3.62.77.83.51.52.27.74.61.62.5-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 8.6%5.7%-1.4%-5.6%
Adj EPS 11.2%4.4%-6%-1.4%
BVPS16.9%16.5%10.3%7.6%
Share Price 11.3% -11.6% -4.2% -11.1%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
20.721.619.217.423.135.52114.913.912.714
Op. Profit
Mgn %
15.816.116.213.514.720.413.411.412.712.212.7
Net Profit
Mgn %
66.86.65.67.712.98.26.16.878
Debt to
Equity
1.41.21.20.90.60.40.50.50.40.50.2
Working Cap
Days
16216219117816916518019520520590
Cash Conv.
Cycle
8176949189829910711211235

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Aarti Drugs Ltd.

Standalone Consolidated
TTM EPS (₹) 20.9 21.8
TTM Sales (₹ Cr.) 2,237 2,477
BVPS (₹.) 147 160.9
Reserves (₹ Cr.) 1,251 1,377
P/BV 2.78 2.54
PE 19.57 18.72
From the Market
52 Week Low / High (₹) 312.50 / 574.95
All Time Low / High (₹) 0.57 / 1025.00
Market Cap (₹ Cr.) 3,727
Equity (₹ Cr.) 91.3
Face Value (₹) 10
Industry PE 40.7

Management X-Ray of Aarti Drugs:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Aarti Drugs - Consolidated Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Aarti Drugs

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales1,1401,1951,2441,5611,8062,1552,4892,7162,5292,387
Operating Expenses 9601,0051,0421,3501,5411,7142,1562,4072,2082,097
Manufacturing Costs142164201227264280359398407411
Material Costs7357447381,0141,1271,2631,6141,8141,6051,467
Employee Cost 404852556166698091100
Other Costs 4348505588106113115105119
Operating Profit 180190202211266440333309321290
Operating Profit Margin (%) 15.8%15.9%16.2%13.5%14.7%20.4%13.4%11.4%12.7%12.2%
Other Income 041215112416
Interest 48403844372624373839
Depreciation 37384043495050505156
Exceptional Items 0004400000
Profit Before Tax 95116125131185369270224236212
Tax 27344241448965586444
Profit After Tax 69828290141280205166172168
PAT Margin (%) 6.0%6.8%6.6%5.7%7.8%13.0%8.2%6.1%6.8%7.0%
Adjusted EPS (₹)7.18.68.79.515.230.122.118.018.718.4
Dividend Payout Ratio (%)24%3%3%3%3%8%5%6%5%5%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 3574004555436529131,0361,1921,2821,369
Share Capital 24242424239393939291
Reserves 3333764325206298209441,1001,1901,278
Minority Interest0000-0-0-0000
Debt450446508471338305495565490556
Long Term Debt191202203208180148138205275284
Short Term Debt258245306263158157356361215272
Trade Payables185197259243330330469480425416
Others Liabilities 110148167198256218208183235233
Total Liabilities 1,1021,1911,3891,4551,5771,7662,2082,4212,4322,575

Fixed Assets

Gross Block7258489099701,0311,1011,1691,2021,3881,496
Accumulated Depreciation232267307345387436479526577630
Net Fixed Assets 493581602625644665690676811866
CWIP 34142833121977210261330
Investments 5121112131719192022
Inventories178210278247325415526516486473
Trade Receivables332297375459489555750865705751
Cash Equivalents 544681022998
Others Assets 557390758584124126141124
Total Assets 1,1021,1911,3891,4551,5771,7662,2082,4212,4322,575

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 1331757014325115570133359245
PBT 95116125131185369270224236212
Adjustment 79727575876971858384
Changes in Working Capital -218-105-3319-186-187-1161034
Tax Paid -20-21-25-30-41-97-83-60-62-55
Cash Flow From Investing Activity -99-107-74-62-33-72-150-164-224-165
Capex -100-107-75-63-37-77-152-165-226-177
Net Investments -0-000300000
Others 11111621212
Cash Flow From Financing Activity -33-684-80-215-819217-136-82
Net Proceeds from Shares 0000000100
Net Proceeds from Borrowing 28953-21-34-760102-7
Interest Paid -44-36-35-40-34-23-21-36-31-33
Dividend Paid -240-2-2-7-23-10-9-9-9
Others 6-4136-41-153-11291-198-32
Net Cash Flow 1-0012213-14-1-2

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)20.6521.619.2417.9723.6535.8121.0314.9313.8712.68
ROCE (%)17.9518.1417.3117.0121.3934.5220.7515.4915.0113.11
Asset Turnover Ratio1.171.120.981.11.191.291.251.171.040.95
PAT to CFO Conversion(x)1.932.130.851.591.780.550.340.82.091.46
Working Capital Days
Receivable Days96899797968896109113111
Inventory Days51557161586369707273
Payable Days87941139093959095103105

Aarti Drugs Ltd Stock News

Aarti Drugs Ltd FAQs

The current trading price of Aarti Drugs on 05-Dec-2025 16:59 is ₹404.9.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Aarti Drugs stood at ₹3,726.6.
The latest P/E ratio of Aarti Drugs as of 04-Dec-2025 is 19.57.
The latest P/B ratio of Aarti Drugs as of 04-Dec-2025 is 2.78.
The 52-week high of Aarti Drugs is ₹575.0 and the 52-week low is ₹312.5.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Aarti Drugs is ₹2,237 ( Cr.) .

About Aarti Drugs Ltd

Aarti Drugs Ltd. was established in the year 1984 and forms part of $900 Million Aarti Group of Industries with robust R&D Division at Tarapur, Maharashtra Industrial Development Corporation (MIDC) in close vicinity to manufacturing locations.

Over the years, the Company has been able to carve a niche for itself and is looking forward to expand the volumes. With the government initiative to encourage private health insurance schemes, consumer spending on medicines is expected to increase, which will spur growth in the generic sector in the domestic market.

The manufacturing-units of Aarti Drugs Ltd. are GMP certified. The Company is also in the process of acquiring an ISO 9002 compliance for all its units and one of the units has already been approved.

The Company aims at becoming the first choice of this expanding market through better products, ensuring quality and timely delivery.

Business area of the company

The company is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Specialty Chemicals and also produces Formulations with its wholly-owned subsidiary - Pinnacle Life Science Private Limited.

Products under APIs includes Ciprofloxacin Hydrochloride, Metronidazole, Metformin HCL, Ketoconazole, Ofloxacin etc. whereas Specialty Chemicals includes Benzene Sulphonyl Chloride, Methyl Nicotinate etc.

Awards and accolades

  • 1991-1992: Outstanding Performance in Export from Chemexcil
  • 2001: Best Vendor from Organization of Pharmaceutical Product
  • 2005: Customer Responsiveness from Avaya Global Connect
  • 2013: Business Partner of the year from Abbott
  • 2014: Appreciation as business partner from Abbott
  • 2014: Certificate of Recognition - Star Export House from Government of India (Ministry of Commerce and Industry)
  • 2015: Business Partner of the year from Abbott
  • 2006: Customer Responsiveness from Avaya Global Connect
  • 2016: Business Partner of the year from Abbott
  • 2016: Outstanding Performance in Export from Pharmexcil
  • 2017: Business Partner of the year from Abbott
  • 2017: Outstanding Performance Latin American Export from Pharmexcil
  • 2018: Business Partner of the year from Abbott

Milestones

  • 1984: Incorporation
  • 1993: Listed On BSE Limited
  • 1996: Amalgamation of Rupal Chemical Industries Limited, Rashesh Chemicals & Pharmaceuticals Limited, Manjarati Chemicals Private Limited, Manjarati Plastisizer Private Limited, Effective Chemicals Private Limited, Star Aluminium Industries Limited and Avez Wire
  • 1998: Turnover of Rs 100 crore
  • 2003: Listed On National Stock Exchange of India Limited
  • 2008: Approval of USFDA Plant
  • 2011: Turnover of Rs 500 crore
  • 2014: Turnover of Rs 1000 crore 100% holdings in Pinnacle Life Science Pvt.  Ltd.
  • 2015: Aarti Drugs Limited -PBT More than Rs 100 crore
  • 2017: Rs 100 crore Turnover Pinnacle Life Science Pvt. Ltd. Pinnacle Life Science (Sikkim) Plant ready for operations
  • 2019: Turnover of Rs 1500 crore
  • 2020: Crossed Rs 2000 crore consolidated turnover and Rs 200 crore formulation turnover
  • 2020: Crossed PAT amounted Rs 200 crore
  • 2022: Consolidated revenue Rs 2500 crore
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×